SCHEMBL6769387

SCHEMBL6769387

O=C1C2Cc3ccccc3CN2C(=O)N1c1cc(Cl)cc(Cl)c1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.67
ALDH1A1 P00352 3/20 0.67
TSHR P16473 1/20 0.63
HTT P42858 1/20 0.60
ADORA2A P29274 1/20 0.54
GRM4 Q14833 1/20 0.54
SIGMAR1 Q99720 4/20 0.49
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
ALOX15 P16050 1/20 0.40
ALOX12 P18054 1/20 0.40
KMT2A Q03164 1/20 0.40
HSD17B10 Q99714 1/20 0.40
DRD2 P14416 1/20 0.40
DRD3 P35462 1/20 0.40
KCNH2 Q12809 1/20 0.40
TAS2R8 Q9NYW2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6769384 1.00 RAB9A (0.67) RAB9AALDH1A1TSHRHTTADORA2A
SCHEMBL13879538 0.89 ALDH1A1 (0.75) RAB9AALDH1A1TSHRHTTADORA2A
SCHEMBL13879530 0.89 RAB9A (0.76) RAB9AALDH1A1TSHRHTTADORA2A
SCHEMBL13879415 0.85 RAB9A (0.79) RAB9AALDH1A1TSHRHTTADORA2A
SCHEMBL6775038 0.81 ALDH1A1 (0.44) RAB9AALDH1A1TSHRHTTGRM4
SCHEMBL14547045 0.81 ALDH1A1 (0.71) RAB9AALDH1A1TSHRHTTADORA2A
SCHEMBL13879404 0.78 TSHR (0.78) RAB9AALDH1A1TSHRHTTADORA2A
SCHEMBL23657643 0.77 RAB9A (0.74) RAB9AALDH1A1TSHRHTTADORA2A
SCHEMBL13879490 0.77 TSHR (1.00) RAB9AALDH1A1TSHRHTTADORA2A
SCHEMBL11502497 0.74 AR (0.47) RAB9AALDH1A1TSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed
WO-2007047146-A2 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. (US) 2007-04-26 WO disclosed
US-6710064-B2 FOR THERAPY OF INFLAMMATORY OR IMMUNE DISEASES BRISTOL-MYERS SQUIBB CO. 2004-03-23 US disclosed
EP-1339718-A1 HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS Bristol-Myers Squibb Company (US) 2003-09-03 EP disclosed
US-20020143035-A1 Hydantoin compounds useful as anti-inflammatory agents BRISTOL-MYERS SQUIBB COMPANY 2002-10-03 US disclosed
WO-2002044181-A1 HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-06-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143035-A1 Hydantoin compounds useful as anti-inflammatory agents HRH4, IL4I1, HRH2 RAB9A 2454/4885ALDH1A1 1272/4885TSHR 4433/4885
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION EIF2AK2, HAVCR2, RTF2 RAB9A 3148/4885ALDH1A1 1500/4885TSHR 4851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.